3 Diagnostics Company, Brake Systems Maker and Aqua Feed Producer Stocks With a Strong Future Roadmap: Thyrocare Technologies, ASK Automotive and Avanti Feeds
- November 18, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Thyrocare Technologies, ASK Automotive and Avanti Feeds: ROE of 18.4% to 27.9% and FY22 to FY26 revenue CAGR of 5.2% to 20.0%. Prices as of 17 Nov 2026.
Quick Answer
The three blood test, brake system and shrimp feed stocks to watch are Thyrocare Technologies, ASK Automotive and Avanti Feeds. Their return on equity ranges from 18.4% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.2% to 20.0%. Thyrocare Technologies has the highest return on equity at 27.9%, while ASK Automotive has the fastest revenue growth at 20.0% a year. Prices are based on the 17 November 2026 close, and this article is educational, not investment advice.
Blood test, brake system and shrimp feed stocks offer a focused view of a sector where demand keeps widening. Thyrocare Technologies, ASK Automotive and Avanti Feeds cover a diagnostics company, a brake systems maker and an aqua feed producer.
This list covers three blood test, brake system and shrimp feed stocks with complete current figures: Thyrocare Technologies, ASK Automotive and Avanti Feeds. Every figure comes from the latest reported financials and the 17 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Blood Test, Brake System and Shrimp Feed Stocks?
Blood test, brake system and shrimp feed stocks are listed companies that run diagnostic labs and test centres, make brake and chassis parts for two wheelers and cars, and make feed for shrimp and fish farms and export shrimp. Their earnings depend on test volumes, vehicle output and aqua farm demand.
Blood Test, Brake System and Shrimp Feed Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Thyrocare Technologies | 506.95 | 7,501 | 42.6 | 59.6 | 27.9 | 0.09 |
| ASK Automotive | 639.85 | 11,184 | 35.4 | 36.9 | 22.7 | 0.52 |
| Avanti Feeds | 727.7 | 9,865 | 16.8 | 33.9 | 18.4 | 0.00 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing blood test, brake system and shrimp feed stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in blood test, brake system and shrimp feed stocks can use the coming numbers to test whether growth is holding.
Why Do Blood Test, Brake System and Shrimp Feed Stocks Have a Strong Roadmap in India?
Blood test, brake system and shrimp feed stocks have a strong roadmap in India because wider use of preventive health tests, rising vehicle output and steady aqua farming keep widening the market for these companies.
- Diagnostics. Doctors order more routine tests.
- Brake systems. Every vehicle needs safe brakes.
- Aqua feed. Shrimp farms need quality feed.
Why Thyrocare Technologies Features Among These Blood Test, Brake System and Shrimp Feed Stocks
Among the blood test, brake system and shrimp feed stocks on this list, Thyrocare Technologies runs a centralised, high-volume testing laboratory in Navi Mumbai and collects samples through a wide partner network of diagnostic centres, pharmacies and franchisees across India.
In the June 2026 quarter, revenue grew 23.5% year on year to Rs 244 crore, while net profit rose 34.1% to Rs 51.3 crore. Revenue rose from Rs 618 crore in FY22 to Rs 846 crore in FY26, a compound annual growth rate of 8.2%.
Net profit grew from Rs 64.4 crore in FY23 to Rs 163 crore in FY26, which works out to a compound annual growth rate of 36.3%. The company has a return on equity of 27.9%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 7,501 crore. The stock trades at a P/E of 42.6, below the industry P/E of 59.6.
Roadmap: The centralised model gives it a low unit cost per test, and the company is adding wellness and preventive health packages along with a growing share of direct-to-consumer bookings. Its partner-led channel lets it scale volumes without building its own collection centres.
What to watch: Track growth in test volume per day and the share of revenue from preventive health packages.
Why ASK Automotive Features Among These Blood Test, Brake System and Shrimp Feed Stocks
Among the diagnostics, auto safety parts and aqua feed shares on this list, ASK Automotive makes brake shoes, brake pads, wheel assemblies and aluminium light-weighting parts, mainly for two-wheelers and with a growing presence in passenger vehicles.
The company has a return on equity of 22.7%, a debt to equity ratio of 0.52 and a market capitalisation of Rs 11,184 crore. The stock trades at a P/E of 35.4, below the industry P/E of 36.9.
Revenue rose from Rs 2,024 crore in FY22 to Rs 4,196 crore in FY26, a compound annual growth rate of 20.0%. Net profit grew from Rs 82.7 crore in FY22 to Rs 297 crore in FY26, which works out to a compound annual growth rate of 37.7%. In the June 2026 quarter, revenue grew 52.1% year on year to Rs 1,361 crore, while net profit rose 28.8% to Rs 85.1 crore.
Roadmap: The company is widening its reach beyond two-wheelers, scaling aluminium parts and adding supply for electric vehicles. Safety content such as disc brakes is rising in new models, which helps revenue per vehicle.
What to watch: Follow two-wheeler industry volumes and progress in new aluminium programmes.
Why Avanti Feeds Features Among These Blood Test, Brake System and Shrimp Feed Stocks
Among the three companies on this list, Avanti Feeds, based in Hyderabad, makes shrimp feed and also processes and exports shrimp, serving aquaculture farmers across India.
Revenue rose from Rs 5,118 crore in FY22 to Rs 6,276 crore in FY26, a compound annual growth rate of 5.2%. Net profit grew from Rs 245 crore in FY22 to Rs 656 crore in FY26, which works out to a compound annual growth rate of 27.9%.
In the June 2026 quarter, revenue grew 18.7% year on year to Rs 1,966 crore. The company has a return on equity of 18.4%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 9,865 crore. The stock trades at a P/E of 16.8, below the industry P/E of 33.9.
Roadmap: India’s aquaculture sector is growing, and demand for quality feed rises with it. The company has a large share of the domestic shrimp feed market and is expanding its processing and exports.
What to watch: Follow export demand and shrimp farm cycles, which affect feed volumes.
Thyrocare Technologies vs ASK Automotive vs Avanti Feeds on Key Financials
The table below sets the three blood test, brake system and shrimp feed stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Thyrocare Technologies | 618 | 846 | 8.2% | 163 | 19.2% |
| ASK Automotive | 2,024 | 4,196 | 20.0% | 297 | 7.1% |
| Avanti Feeds | 5,118 | 6,276 | 5.2% | 656 | 10.4% |
Thyrocare Technologies posts the highest return on equity in this group at 27.9%. Avanti Feeds has the largest FY26 revenue at Rs 6,276 crore, and ASK Automotive shows the fastest revenue growth with a 20.0% compound annual rate. A useful habit with blood test, brake system and shrimp feed stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several pathology tests, vehicle brakes and fish feed stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Thyrocare Technologies | 198 | 244 | 23.5% |
| ASK Automotive | 895 | 1,361 | 52.1% |
| Avanti Feeds | 1,656 | 1,966 | 18.7% |
Key Risks to Check Before Investing in Blood Test, Brake System and Shrimp Feed Stocks
Every theme carries risks that deserve a check before any decision. For these blood test, brake system and shrimp feed stocks, the main points are: Long-term diagnostics, auto safety parts and aqua feed shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Test volumes. Footfall and test mix can vary with seasons.
- Demand cycles. Sales can vary with seasons and rates.
- Farm cycles. Tractor and crop input demand follows the monsoon and farm incomes.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter blood test, brake system and shrimp feed stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Blood Test, Brake System and Shrimp Feed Stocks
Blood test, brake system and shrimp feed stocks reward patient research into demand, execution and financial strength. Thyrocare Technologies, ASK Automotive and Avanti Feeds each have a clear plan to grow. Based on the 17 November 2026 close, Thyrocare Technologies trades at Rs 506.95, ASK Automotive at Rs 639.85 and Avanti Feeds at Rs 727.7. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these blood test, brake system and shrimp feed stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track blood test, brake system and shrimp feed stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are blood test, brake system and shrimp feed stocks?
Ans. Blood test, brake system and shrimp feed stocks are listed companies that run diagnostic labs and test centres, make brake and chassis parts for two wheelers and cars, and make feed for shrimp and fish farms and export shrimp. Their earnings depend on test volumes, vehicle output and aqua farm demand. This list looks at three of them, Thyrocare Technologies, ASK Automotive and Avanti Feeds, using reported FY22 to FY26 financials and the 17 November 2026 closing prices.
Which blood test, brake system and shrimp feed stocks are covered in this list?
Ans. This list covers Thyrocare Technologies, ASK Automotive and Avanti Feeds. Based on the 17 November 2026 close, Thyrocare Technologies traded at Rs 506.95, ASK Automotive at Rs 639.85 and Avanti Feeds at Rs 727.7. Their return on equity ranges from 18.4% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.2% to 20.0%.
Why do blood test, brake system and shrimp feed stocks have a strong future roadmap in India?
Ans. Blood test, brake system and shrimp feed stocks have a strong roadmap in India because wider use of preventive health tests, rising vehicle output and steady aqua farming keep widening the market for these companies. The main drivers are as follows. Diagnostics. Doctors order more routine tests. Brake systems. Every vehicle needs safe brakes. Aqua feed. Shrimp farms need quality feed. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Thyrocare Technologies performed financially?
Ans. Revenue rose from Rs 618 crore in FY22 to Rs 846 crore in FY26, a compound annual growth rate of 8.2%. Net profit grew from Rs 64.4 crore in FY23 to Rs 163 crore in FY26, which works out to a compound annual growth rate of 36.3%. In the June 2026 quarter, revenue grew 23.5% year on year to Rs 244 crore, while net profit rose 34.1% to Rs 51.3 crore. The company has a return on equity of 27.9%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 7,501 crore. The stock trades at a P/E of 42.6, below the industry P/E of 59.6. Looking ahead, the centralised model gives it a low unit cost per test, and the company is adding wellness and preventive health packages along with a growing share of direct-to-consumer bookings. Its partner-led channel lets it scale volumes without building its own collection centres.
How has ASK Automotive performed financially?
Ans. Revenue rose from Rs 2,024 crore in FY22 to Rs 4,196 crore in FY26, a compound annual growth rate of 20.0%. Net profit grew from Rs 82.7 crore in FY22 to Rs 297 crore in FY26, which works out to a compound annual growth rate of 37.7%. In the June 2026 quarter, revenue grew 52.1% year on year to Rs 1,361 crore, while net profit rose 28.8% to Rs 85.1 crore. The company has a return on equity of 22.7%, a debt to equity ratio of 0.52 and a market capitalisation of Rs 11,184 crore. The stock trades at a P/E of 35.4, below the industry P/E of 36.9. Looking ahead, the company is widening its reach beyond two-wheelers, scaling aluminium parts and adding supply for electric vehicles. Safety content such as disc brakes is rising in new models, which helps revenue per vehicle.
How has Avanti Feeds performed financially?
Ans. Revenue rose from Rs 5,118 crore in FY22 to Rs 6,276 crore in FY26, a compound annual growth rate of 5.2%. Net profit grew from Rs 245 crore in FY22 to Rs 656 crore in FY26, which works out to a compound annual growth rate of 27.9%. In the June 2026 quarter, revenue grew 18.7% year on year to Rs 1,966 crore. The company has a return on equity of 18.4%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 9,865 crore. The stock trades at a P/E of 16.8, below the industry P/E of 33.9. Looking ahead, india’s aquaculture sector is growing, and demand for quality feed rises with it. The company has a large share of the domestic shrimp feed market and is expanding its processing and exports.
What risks should investors check before buying blood test, brake system and shrimp feed stocks?
Ans. Investors should check a few risks before buying blood test, brake system and shrimp feed stocks. Test volumes. Footfall and test mix can vary with seasons. Demand cycles. Sales can vary with seasons and rates. Farm cycles. Tractor and crop input demand follows the monsoon and farm incomes. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of blood test, brake system and shrimp feed stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 17 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.